Status:
TERMINATED
UPMC OPTIMISE-C19 Trial, a COVID-19 Study
Lead Sponsor:
Erin McCreary
Collaborating Sponsors:
University of Pittsburgh
Conditions:
Covid19
Eligibility:
All Genders
12-120 years
Phase:
PHASE4
Brief Summary
Multiple monoclonal antibodies (mABs) have been shown to reduce viral burden and improve clinical outcomes, have been granted FDA Emergency Use Authorization (EUA) for use in select populations, and a...
Detailed Description
While COVID-19 vaccination will reduce COVID-19-related morbidity and mortality, the learned immune response may vary between individuals. This means interventions such as monoclonal antibodies (mAB) ...
Eligibility Criteria
Inclusion
- COVID-19 positive patients
- Eligible for mAB under FDA EUA
Exclusion
- Death is deemed to be imminent or inevitable
- Previous participation in this REMAP within the last 90 days
Key Trial Info
Start Date :
March 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 16 2022
Estimated Enrollment :
4571 Patients enrolled
Trial Details
Trial ID
NCT04790786
Start Date
March 10 2021
End Date
June 16 2022
Last Update
June 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC
Pittsburgh, Pennsylvania, United States, 15213